AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19773703 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home palliative care respite service delivered by enrolled nurses
Number of subjects: 0
Study 17504124 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular targeted drugs (e.g., Glivec/Imatinib)
Number of subjects: 0
Study 17504124 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy drugs
Number of subjects: 0
Study 14613632 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 15
Study 14613632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 15
Study 14613632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10100270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (5 mg/m2 30 min before chemotherapy, then 4 mg/m2 every 8 h i.v.)
Number of subjects: 23
Study 10100270 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron (0.2 mg/kg 30 min before chemotherapy, max dose 5 mg)
Number of subjects: 23
Study 8733993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate 200 micrograms once daily
Number of subjects: 232
Study 8733993 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 232
Study 8733993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 1853146 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole once daily
Number of subjects: 98
Study 1853146 — intervention group
Group type: COMPARATOR
Intervention: 300 mg ranitidine twice daily
Number of subjects: 98
Study 1853146 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily (maintenance treatment)
Number of subjects: 98
Study 1853146 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine twice daily (maintenance treatment)
Number of subjects: 98
Study 6853983 — intervention group
Group type: EXPERIMENTAL
Intervention: Routinely sterilized dilators
Number of subjects: 17
Study 6853983 — intervention group
Group type: COMPARATOR
Intervention: Resterilized dilators
Number of subjects: 17
Study 29428426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy (Pylera)
Number of subjects: 60
Study 29428426 — intervention group
Group type: COMPARATOR
Intervention: 14-days sequential therapy
Number of subjects: 60
Study 26949703 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (0.005 μg/kg/min before contrast media exposure and saline hydration)
Number of subjects: 209
Study 26949703 — intervention group
Group type: COMPARATOR
Intervention: Saline hydration alone (control)
Number of subjects: 209
Study 25918703 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPLETE RevitaLens
Number of subjects: 31
Study 25918703 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergi
Number of subjects: 31
Study 25918703 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist
Number of subjects: 31
Study 23018437 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A‐adjuvanted H1N1v vaccine (3.75 μg haemagglutinin)
Number of subjects: 306
Study 23018437 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted H1N1v vaccine (15 μg haemagglutinin)
Number of subjects: 306
Study 23018437 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A‐adjuvanted H1N1v vaccine
Number of subjects: 306
Study 23018437 — intervention group
Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 306
Study 21432588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training condition
Number of subjects: 29
Study 21432588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training condition
Number of subjects: 29
Study 18613246 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginalized random effects models (MREMs) for longitudinal ordinal data
Number of subjects: 0
Study 18613246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture model for joint distribution of longitudinal measures and progression/death times
Number of subjects: 0
Study 15884024 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Participation (GP)
Number of subjects: 42
Study 15884024 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 42
Study 12911461 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDA-antagonist memantine
Number of subjects: 16
Study 12911461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Respiratory Distress Syndrome (ARDS) patients (n=19)
Number of subjects: 70
Study 10579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Lung Injury (ALI) patients (n=33)
Number of subjects: 70
Study 10579266 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (n=70)
Number of subjects: 70
Study 8684799 — intervention group
Group type: EXPERIMENTAL
Intervention: C3F8 gas
Number of subjects: 321
Study 8684799 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 321
Study 8684799 — intervention group
Group type: COMPARATOR
Intervention: Posterior PVR
Number of subjects: 321
Study 8684799 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior PVR
Number of subjects: 321
Study 1815879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 46
Study 1815879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 6617715 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg)
Number of subjects: 6
Study 6617715 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.2 mg/kg)
Number of subjects: 6
Study 31244352 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 181
Study 31244352 — intervention group
Group type: COMPARATOR
Intervention: midwife counseling
Number of subjects: 181
Study 29863591 — intervention group
Group type: EXPERIMENTAL
Intervention: BANDS
Number of subjects: 12
Study 29863591 — intervention group
Group type: EXPERIMENTAL
Intervention: CS + BANDS
Number of subjects: 12
Study 29863591 — intervention group
Group type: EXPERIMENTAL
Intervention: CS30
Number of subjects: 12
Study 29863591 — intervention group
Group type: COMPARATOR
Intervention: CS (traditional set with continuous repetitions)
Number of subjects: 12
Study 27787873 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 317
Study 27787873 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 317
Study 27787873 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery without NAC
Number of subjects: 317
Study 25421427 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDHP
Number of subjects: 20
Study 25421427 — intervention group
Group type: EXPERIMENTAL
Intervention: LHDHP
Number of subjects: 20
Study 23578890 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1498
Study 23578890 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chromium bare metal stent (BMS)
Number of subjects: 1498
Study 23578890 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stent thrombosis (ST)
Number of subjects: 1498
Study 23578890 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS implantation
Number of subjects: 1498
Study 23578890 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment resolution of at least 70% in the EKG post-PCI
Number of subjects: 1498
Study 23578890 — intervention group
Group type: EXPERIMENTAL
Intervention: High Killip class on admission
Number of subjects: 1498
Study 22235600 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiostethoscope
Number of subjects: 2
Study 19606406 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 622
Study 16386740 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-pain-reducing program (BPRP)
Number of subjects: 56
Study 16386740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 12754030 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vancomycin (500mg)
Number of subjects: 14
Study 11003358 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg on day 0 and day 4 posttransplantation)
Number of subjects: 722
Study 9104973 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization
Number of subjects: 200
Study 1448311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin (20 mg/kg/day for 4 days)
Number of subjects: 0
Study 1448311 — intervention group
Group type: COMPARATOR
Intervention: Topical chloramphenicol
Number of subjects: 0
Study 3887552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:3 jejunoileal ratio
Number of subjects: 89
Study 3887552 — intervention group
Group type: EXPERIMENTAL
Intervention: 3:1 jejunoileal ratio
Number of subjects: 89
Study 3887552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 89
Study 3887552 — intervention group
Group type: EXPERIMENTAL
Intervention: Long jejunum and short ileum segment
Number of subjects: 89
Study 31475502 — intervention group
Group type: EXPERIMENTAL
Intervention: AirLoc brace
Number of subjects: 39
Study 31475502 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 39
Study 28502739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry participants with social proof heuristic
Number of subjects: 0
Study 28502739 — intervention group
Group type: COMPARATOR
Intervention: Hungry participants without social proof heuristic
Number of subjects: 0
Study 26059337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 106
Study 26059337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 106
Study 26059337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 106
Study 26059337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 24100910 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL) method
Number of subjects: 30
Study 24100910 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL) method
Number of subjects: 30
Study 21357819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with LBBB
Number of subjects: 1817
Study 21357819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with non-LBBB
Number of subjects: 1817
Study 21357819 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1817
Study 19663668 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid therapy
Number of subjects: 311
Study 17024642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle foot orthoses (AFO)
Number of subjects: 8
Study 17024642 — intervention group
Group type: COMPARATOR
Intervention: No ankle foot orthoses (without AFO)
Number of subjects: 8
Study 14756598 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological adjustment
Number of subjects: 287
Study 14756598 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical adjustment
Number of subjects: 287
Study 14756598 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a factor
Number of subjects: 287
Study 14756598 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal resources (self-image, optimism, perceived control)
Number of subjects: 287
Study 14756598 — intervention group
Group type: EXPERIMENTAL
Intervention: Social resources (social support)
Number of subjects: 287
Study 11772140 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (25, 50, 75, and 100 microg/h, replaced every 3 days)
Number of subjects: 0
Study 11772140 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 0
Study 11772140 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release oral morphine
Number of subjects: 0
Study 10223542 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha2b (3 MU three times weekly, intramuscularly)
Number of subjects: 242
Study 10223542 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 242
Study 10223542 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha2b
Number of subjects: 242
Study 7603933 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education leaflet
Number of subjects: 0
Study 7603933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 0
Study 2204343 — intervention group
Group type: EXPERIMENTAL
Intervention: Enciprazine (D 13 112), dosage not specified
Number of subjects: 0
Study 2204343 — intervention group
Group type: EXPERIMENTAL
Intervention: Enciprazine (D 13 112), highest dosage
Number of subjects: 0
Study 533862 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim resistance (more resistance)
Number of subjects: 229
Study 533862 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim resistance (completed rape)
Number of subjects: 229
Study 533862 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim resistance (attempted rape)
Number of subjects: 229
Study 533862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex of observer (women)
Number of subjects: 229
Study 533862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex of observer (men)
Number of subjects: 229
Study 31064014 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NME (NME1)
Number of subjects: 432
Study 31064014 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% NME (NME2)
Number of subjects: 432
Study 31064014 — intervention group
Group type: COMPARATOR
Intervention: 0% NME (Control)
Number of subjects: 432
Study 28301282 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg hepatitis B vaccine (IM20 group)
Number of subjects: 0
Study 28301282 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg hepatitis B vaccine (IM60 group)
Number of subjects: 0
Study 28301282 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 0
Study 25436624 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise 1 (ECC1)
Number of subjects: 16
Study 25436624 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise 2 (ECC2)
Number of subjects: 16
Study 25436624 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (no exercise)
Number of subjects: 16
Study 25436624 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (both ECC1 and ECC2)
Number of subjects: 16
Study 23905376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Tiaojing Recipe (BTR) and GnRHa/FSH/hCG
Number of subjects: 66
Study 23905376 — intervention group
Group type: COMPARATOR
Intervention: GnRHa/FSH/hCG
Number of subjects: 66
Study 21492926 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months' open-label isoniazid followed by 30 months' masked isoniazid
Number of subjects: 1995
Study 21492926 — intervention group
Group type: COMPARATOR
Intervention: 6 months' open-label isoniazid followed by 30 months' masked placebo
Number of subjects: 1995
Study 21492926 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 days of antiretroviral therapy
Number of subjects: 1995
Study 21492926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test positive participants receiving continued isoniazid treatment
Number of subjects: 1995
Study 21492926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test negative participants receiving continued isoniazid treatment
Number of subjects: 1995
Study 19621658 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-multidetector computed tomography (MDCT) with cholangiography and angiography
Number of subjects: 75
Study 16717465 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tirofiban administration (n = 32)
Number of subjects: 66
Study 16717465 — intervention group
Group type: COMPARATOR
Intervention: Late tirofiban administration (n = 34)
Number of subjects: 66
Study 14644853 — intervention group
Group type: COMPARATOR
Intervention: Gym based resistance exercise programme
Number of subjects: 105
Study 14644853 — intervention group
Group type: COMPARATOR
Intervention: Hydrotherapy resistance exercise programme
Number of subjects: 105
Study 14644853 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 105
Study 10795728 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (0.65 mg/kg)
Number of subjects: 23
Study 10795728 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 microg/kg)
Number of subjects: 23
Study 10795728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8690832 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who entered the study (528)
Number of subjects: 528
Study 8690832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical studies with different degrees of selection bias
Number of subjects: 528
Study 2061566 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (450 mg/day)
Number of subjects: 7
Study 6635447 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for three days
Number of subjects: 54
Study 6635447 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 600 mg plus trimethoprim 160 mg once daily for three days
Number of subjects: 54
Study 6635447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rifampin 600 mg plus trimethoprim 160 mg
Number of subjects: 54
Study 3842545 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 G of salt in the morning and a placebo in the evening
Number of subjects: 216
Study 3842545 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in the morning and 2 G of salt in the evening
Number of subjects: 216
Study 3842545 — intervention group
Group type: COMPARATOR
Intervention: Placebo at both times
Number of subjects: 216
Study 31733583 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-20M culture medium for morphological identification of S. mutans
Number of subjects: 266
Study 31733583 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-20M culture medium for morphological identification of S. sobrinus
Number of subjects: 266
Study 31733583 — intervention group
Group type: COMPARATOR
Intervention: Biochemical identification (biotyping) and proteomic identification by MALDI-TOF mass spectrometry
Number of subjects: 266
Study 30527827 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing (7 quizzes over one academic year)
Number of subjects: 0
Study 30527827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no quizzes)
Number of subjects: 0
Study 30527827 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey responses
Number of subjects: 0
Study 27098818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo wii (NW) gaming
Number of subjects: 105
Study 27098818 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Number of subjects: 105
Study 27098818 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 24607708 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Maximum Restraint (PMR) position
Number of subjects: 10
Study 24607708 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 10
Study 24607708 — intervention group
Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 10
Study 22437792 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin (rsCT) tablets (0.2 mg/d) plus placebo nasal spray
Number of subjects: 565
Study 22437792 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (ssCT) nasal spray (200 IU/d) plus placebo tablets
Number of subjects: 565
Study 22437792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo tablets plus placebo nasal spray)
Number of subjects: 565
Study 22437792 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin (rsCT) tablets
Number of subjects: 565
Study 22437792 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 565
Study 21331988 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum
Number of subjects: 61
Study 21331988 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 61
Study 18333888 — intervention group
Group type: EXPERIMENTAL
Intervention: PHX1149 100 mg
Number of subjects: 0
Study 18333888 — intervention group
Group type: EXPERIMENTAL
Intervention: PHX1149 200 mg
Number of subjects: 0
Study 18333888 — intervention group
Group type: EXPERIMENTAL
Intervention: PHX1149 400 mg
Number of subjects: 0
Study 18333888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15747700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach nerve block
Number of subjects: 60
Study 15747700 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach nerve block
Number of subjects: 60
Study 15747700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 60
Study 12556153 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolysis (nerve release)
Number of subjects: 500000
Study 12556153 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no intervention)
Number of subjects: 500000
Study 10371259 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol day (0.35 g/kg of 95% alcohol)
Number of subjects: 26
Study 10371259 — intervention group
Group type: COMPARATOR
Intervention: Placebo day (1 ml of alcohol in 240 ml beverages)
Number of subjects: 26
Study 8877028 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan (glu‐5‐HTP)
Number of subjects: 9
Study 8877028 — intervention group
Group type: COMPARATOR
Intervention: gamma‐L‐glutamyl-L‐tryptophan (glu‐TRP)
Number of subjects: 9
Study 8877028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1673736 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued antiepileptic treatment
Number of subjects: 1013
Study 1673736 — intervention group
Group type: COMPARATOR
Intervention: Slow withdrawal of antiepileptic treatment
Number of subjects: 1013
Study 6873851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolo Visano Supp. sine codeino
Number of subjects: 0
Study 6873851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolo Visano Supp. (with codeine)
Number of subjects: 0
Study 6873851 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 0